Intraocular pressure reduction in chronic simple glaucoma by continuous infusion of dilute pilocarpine solution

A. T. BIRMINGHAM, N. R. GALLOWAY,† and D. A. WALKER
From the Department of Physiology and Pharmacology, Medical School, Queen’s Medical Centre, Nottingham, and the †Eye Hospital, Nottingham

Summary Ten hospital outpatients with bilateral chronic simple glaucoma received a single drop of 2% pilocarpine to one eye and a continuous infusion of 0.1% pilocarpine at a flow rate of 0.01 ml/min to the other eye (both solutions were at pH 7.2). On another occasion the treatments were reversed. Measurements of intraocular pressure (IOP) and pupil diameter were made at 30 min intervals for 2 hours. The continuous infusion of dilute solution was as effective as the single drop of more concentrated solution in reducing IOP and in constricting the pupil; the drop was somewhat faster in producing its effect.

It has previously been shown in normal persons that the technique of continuous infusion of a dilute solution of pilocarpine at a rate which does not produce overflow from the conjunctival sac can be as effective as a pupilloconstrictor as a single drop of a more concentrated solution (Birmingham et al., 1976a). We now report an investigation of the effectiveness of continuous infusion of dilute pilocarpine in lowering the intraocular pressure in elderly hospital outpatients with chronic simple glaucoma. A preliminary account of this work has been presented elsewhere (Birmingham et al., 1976b).

Patients and methods

The subjects were 10 outpatients of the Glaucoma Clinic at Nottingham Eye Hospital who had a diagnosis of bilateral chronic simple glaucoma which was controlled by pilocarpine eye drops. There were 6 men and 4 women and their ages ranged from 63 to 83 years (mean 71.4 years). They gave their informed consent to participate in a comparison of the effect of a single drop of 2% pilocarpine at pH 7-2 with that of an infusion at 0-01 ml/min of 0-1% pilocarpine at pH 7-2. A cross-over design was used so that each eye received the single drop on one occasion and the infusion on another.

The patients were asked to attend the clinic on 3 separate occasions at weekly intervals. The time of day was the same for each visit to minimise any effect of diurnal variation. At the first visit the patients were on their usual treatment, and 3 measurements of intraocular pressure (IOP) of both eyes were made at 30 min intervals to establish controlled baseline IOP. The patients were asked to stop using their drops for the 3 days preceding each of the next 2 visits. At the second visit, after 1 measurement of IOP and pupil diameter of each eye, an infusion of 0.1% pilocarpine at 0.01 ml/min was begun to the right eye and a single drop of 2% pilocarpine was administered to the left eye. The infusion was continued for 2 hours and readings of IOP and pupil diameter were made for both eyes at 30 min intervals. At the third visit the procedure followed during the second visit was repeated except that the right eye received the single drop administration and the left eye received the continuous infusion. At the end of the third visit the patients were told to return to their usual treatment.

Five healthy volunteers with no history of eye disease except mild refractive errors, who did not wear contact lenses, took part in a separate investigation of the effects on bilateral pupil diameter of an infusion of 0.1% pilocarpine at pH 7-2 for 2 hours into the left eye. Pupil diameter was measured every 5 min.

Correspondence to Professor A. T. Birmingham, Department of Physiology and Pharmacology, Medical School, Queen’s Medical Centre, Nottingham NG7 2UH.
MEASUREMENT OF INTRAOCULAR PRESSURE AND PUPIL DIAMETER
For the patients at the Glaucoma Clinic the IOP was measured by application tonometry (Goldmann tonometer) under 0-5% proparacaine local anaesthesia. Pupil diameter was measured by direct observation through the calibrated graticule of the telescope of a Goldmann perimeter under controlled white light illumination.

In the normal volunteers the pupil diameter was measured under low intensity red light illumination in a dark room. The pupil was observed through a low-power binocular microscope (×5 eyepieces, ×1:25 objectives) suspended above the eye. One eyepiece was fitted with a graticule to allow direct measurement of the diameter of the pupil in the field of view.

INFUSION TECHNIQUE
This was identical to that described by Birmingham et al. (1976a). The solution was contained in a sterile 1 ml syringe compressed by a motor driven syringe ram at a rate to provide a flow of 0-01 ml/min. The fluid was delivered to the conjunctival sac of the eye being infused by means of sterile small-bore silicone elastomer tubing (Silastic No. 602-101, Dow Corning) of about 2 m length. The distal end of the tubing rested in the inner canthus of the eye and was held in place by adhesive tape attached to the nose and forehead.

When a patient needed to move between rooms at 1-hourly intervals for measurements of IOP and pupil diameter, the infusion was briefly interrupted and the syringe was temporarily removed from the syringe ram and clipped to the patient's clothing.

PILOCARPIN SOLUTIONS AND DOSES
The sterile solutions of pilocarpine hydrochloride were specially formulated to a pH of 7-2 by the addition of borate buffer. Owing to the much shorter shelf life of pilocarpine at near neutral pH than at its natural more acid pH (Riegelman and Vaughan, 1958; Cowle and Anderson, 1967) the solution was provided in 2 bottles, the contents of which were mixed immediately before use. One bottle contained the pilocarpine solution at its natural pH at twice the final concentration required, the other bottle contained an equal volume of an appropriate borate buffer and sodium chloride solution. On mixing the 2 solutions, a sterile solution, isotonic with tears, having a pH of 7-2 and pilocarpine concentration of 2% or 0.1% was obtained.

After the recording of baseline measurements the patients received one drop (0-05 ml) of 2% pilocarpine (dose 1 mg) to one eye and the infusion of 0-1% pilocarpine at 0-01 ml/min (dose 1 mg after 100 min) to the other eye. This procedure was reversed for the 2 eyes on the third visit.

The normal subjects received only the 0-1% pilocarpine infusion to the left eye on 1 occasion.

Results
COMPARISON OF THE OCULAR HYPOTENSIIVE EFFECTS OF PILOCARPINE AT PH 7-2 GIVEN AS A SINGLE DROP OR AS AN INFUSION
The means of the 3 measurements of IOP made on both eyes when the 10 patients were on their usual treatment for their glaucoma were 18-8 mmHg for right eyes and 19-1 mmHg for left eyes (Table 1). When the effects of 3 days, on 2 occasions at weekly intervals, the IOP rose in both eyes. The rise in pressure in the right eyes was statistically significant; the rise in pressure in the left eyes was smaller and did not achieve statistical significance (Table 1).

The single drop of 2% pilocarpine and the continuous infusion of 0-1% pilocarpine reduced the IOP of both eyes and the effect increased with time over the period of observation (Fig. 1). At each 30 min point of measurement after the start of treatment the means of the differences between pretreatment measurements and post-treatment measurements for either the single drop or the continuous infusion were statistically significant (Table 2). When the effects of the 2 treatments were compared, the degree of fall in pressure at each time of measurement was the same in the left eyes whether they had received the drop or the infusion. For the right eyes the fall in pressure was greater at 30 and at 60 mm for the drop compared with the infusion (this difference was statistically significant

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Means (with one standard deviation) for right and left eyes (n=10) of intraocular pressure measurements made while taking standard treatment and after interrupting treatment for 3 days</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1st Visit, While receiving usual drops</td>
</tr>
<tr>
<td>Right eyes (n=10)</td>
<td>18-8 (4-5)</td>
</tr>
<tr>
<td>Left eyes (n=10)</td>
<td>19-1 (3-9)</td>
</tr>
</tbody>
</table>

Differences (paired t tests) between:

<table>
<thead>
<tr>
<th></th>
<th>1st and 2nd Visits</th>
<th>1st and 3rd Visits</th>
</tr>
</thead>
<tbody>
<tr>
<td>Right eyes</td>
<td>0-02 &gt; P &gt; 0-01</td>
<td>0-02 &gt; P &gt; 0-01</td>
</tr>
<tr>
<td>Left eyes</td>
<td>0-2 &gt; P &gt; 0-1</td>
<td>0-1 &gt; P &gt; 0-05</td>
</tr>
</tbody>
</table>
only at 60 min) but was not greater at 90 and 120 min. Thus it appears that the rate of effect and the degree of effect of the 2 treatments were the same in left eyes, whereas in right eyes the rate of onset of effect was greater for the single drop but the eventual degree of effect was no different from that achieved by the infusion.

**Fig. 1** Means (± SEM) of intraocular pressures of the eyes of 10 patients with bilateral chronic simple glaucoma. The pressure at zero time was that recorded, after 3 days with no treatment, immediately preceding the instillation of 1 drop containing 1 mg pilocarpine at pH 7.2 or the start of an infusion of a 0.1% solution of pilocarpine at 10 μg/min at pH 7.2. Treatments were reversed between first (upper graph) and second (lower graph) sets of measurements, which were separated by an interval of 1 week. Intraocular pressure was measured every 30 min. The solid horizontal lines indicate the means of the controlled intraocular pressures of right eyes (RE) on regular treatment with pilocarpine drops and the broken horizontal lines those for left eyes (LE).

**Effect on Pupil Diameter**

For the patients the effect of either treatment was to reduce pupil diameter. This reduction was statistically significant at the first post-drug measurement at 30 min for all eyes and remained so for the next 3 measurements (Table 3). When the treatments were compared, there was a significantly greater pupilloconstrictor effect of the drop than from the infusion in left eyes at 60 min only and in right eyes at 60 and at 90 min (notes a, b, and c, Table 3).

For the 5 normal subjects an infusion of 0.1% pilocarpine to the left eye rapidly reduced pupil diameter to a mean of some 30% of control diameter by 50 min after the start of the infusion. This reduction persisted until the cessation of the infusion. Throughout the 120 min of infusion to the left eyes there was no change in diameter of the pupils of the untreated right eyes.

**Discussion**

From this comparison of 2 methods of administering pilocarpine the general conclusion seems to be that a continuous infusion of a dilute solution is as effective as a single drop of a more concentrated solution. For a fair comparison of the 2 methods it was necessary to administer the same dose to each eye. When the interruptions of the infusion which were necessary for IOP and pupil diameter measurements are taken into account, the dose delivered by the 2% drop or the 0.1% infusion was the same at 1 mg. Because of the pronounced influence of pH on pilocarpine absorption (Anderson and Cowle, 1968; Birmingham et al., 1976a) it was necessary to make the pH of both the concentrated drop and the dilute infusion the same (pH 7.2) at a value close to that of tears.

It is unlikely that the patients' usual treatment was still exerting an effect 3 days after stopping the drops. Drance et al. (1974) showed that 15 h after the high dose of a drop of 8% pilocarpine the IOP had returned to within 90% of the pre-drug value. After stopping the usual treatment for 3 days the expected difference in pressure between the 2 eyes was found. Davanger (1965) in an extensive study reported a mean difference in pressure between the 2 eyes of patients with glaucoma of 2-8 mmHg. In the present small series the mean differences were 3-4 mmHg at the second visit and 2-9 mmHg at the third visit.

The appropriateness of a 2 h period for the measurement of the effects of the treatments is supported by the finding of Drance and Nash (1971), who measured the effect of 2% pilocarpine for 8 hours but found the effect to be maximal at 2 hours. Fenton and Schwartz (1963) found the
Intraocular pressure reduction in chronic simple glaucoma

Table 2  Means (with standard deviation) for the right and left eyes of differences between IOP (mmHg) after interrupting treatment for 3 days and IOPs at 30, 60, 90, and 120 min after beginning of infusion or application of drop. The same 10 patients attended for the 2nd and 3rd visits

<table>
<thead>
<tr>
<th></th>
<th>2nd Visit</th>
<th>3rd Visit</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>30 min</td>
<td>60 min</td>
</tr>
<tr>
<td>Right eyes (n=10) (0-1% infusion)</td>
<td>2.6 (3.0)</td>
<td>4.9 (2.8)</td>
</tr>
<tr>
<td>Paired t-test</td>
<td>P&lt;0.025 &gt;P&gt;0.02</td>
<td>P&lt;0.001</td>
</tr>
<tr>
<td>Left eyes (n=10) (2-0% drop)</td>
<td>2.5 (3.1)</td>
<td>4.3 (2.3)</td>
</tr>
<tr>
<td>Paired t-test</td>
<td>P&lt;0.025 &gt;P&gt;0.025</td>
<td>P&lt;0.001</td>
</tr>
</tbody>
</table>

Table 3  Means (with one standard deviation) for right and left eyes of pupil diameters (mm) after interrupting treatment for 3 days and at 30, 60, 90, and 120 min after beginning of infusion or application of drop. The same 10 patients attended for the 2nd and 3rd visits

<table>
<thead>
<tr>
<th></th>
<th>2nd Visit</th>
<th>3rd Visit</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Pre-drug</td>
<td>Time after exposure to drug</td>
</tr>
<tr>
<td></td>
<td>30 min</td>
<td>60 min</td>
</tr>
<tr>
<td>Right eyes (n=10) (0-1% infusion)</td>
<td>3.3 (0.6)</td>
<td>2.2 (0.6)</td>
</tr>
<tr>
<td>Paired t-test</td>
<td>P&lt;0.001</td>
<td>P&lt;0.001</td>
</tr>
<tr>
<td>Left eyes (n=10) (2-0% drop)</td>
<td>3.2 (0.7)</td>
<td>2.3 (0.8)</td>
</tr>
<tr>
<td>Paired t-test</td>
<td>P&lt;0.001</td>
<td>P&lt;0.001</td>
</tr>
<tr>
<td>Right eyes (n=10) (2-0% drop)</td>
<td>3.2 (0.7)</td>
<td>2.6 (0.6)</td>
</tr>
<tr>
<td>Paired t-test</td>
<td>P&lt;0.001</td>
<td>P&lt;0.001</td>
</tr>
<tr>
<td>Left eyes (n=10) (0-1% infusion)</td>
<td>3.2 (0.5)</td>
<td>2.6 (0.6)</td>
</tr>
<tr>
<td>Paired t-test</td>
<td>P&lt;0.001</td>
<td>P&lt;0.001</td>
</tr>
</tbody>
</table>

Within eyes there was a significantly greater pupilloconstrictor effect of the 2% drop compared with the 0-1% infusion at 60 min (a, 0.05 >P>0.025; b, P<0.001) for both eyes and at 90 min (c, 0.025 >P>0.02) for right eyes.

Effect of 2% pilocarpine to reach 'a steady state' at 75 min in 10 patients with glaucoma. Thus in the present investigation the effect of the infusion was compared at 2 hours with the likely maximal effect of the single drop. At the end of this 2 hour period the hypotensive effect of the 2 treatments was similar: in right eyes the mean falls in IOP were 8.7 mmHg for the infusion and 9.0 mmHg for the drop, in left eyes the corresponding values were 7.1 and 7.0 mmHg. The rate of achievement of this fall was greater for the drop than for the infusion in right eyes but the same in left eyes.

Change in pupil diameter was measured as another index of entry of drug into the eye. Again the effect of the 2 treatments was similar at the end of 2 hours: in right eyes the mean pupilloconstrictor effects were 1.4 mm for the infusion and 1.6 mm for the drop, while the corresponding figures for
left eyes were 1·1 and 1·3 mm. During the 2 hour period the greater effect of the drop at 60 min (both eyes) and at 90 min (right eyes only) suggests a faster rate of effect for the drop.

It is not surprising that there were some differences in the rate of onset of effect. Although the final dose at the end of 2 hours was the same, the initial concentration produced by the 2% drop would be higher than that produced by the 0·1% infusion. Schumacher (1966) found that pilocarpine (pH 4·2) could be detected in the aqueous of rabbits within 3–5 min of instillation of a single drop into the conjunctival sac. Van Hoose and Leaders (1974) suggested that the release of drug from the endothe
telial surface of the cornea depended on the concentration of the drug to which the cornea was exposed. The cornea was seen to act as a reservoir for the drug. The effectiveness of a 2% drop will decline after 2 hours (Drance and Nash, 1971), whereas that of an infusion will continue for as long as the infusion is continued.

The observations on the time course of the effects of a single drop or an infusion on IOP and pupil diameter in patients with glaucoma are consistent with those for pupil diameter in normal subjects. Birmingham et al. (1976a) found the maximum effect of a single drop of 0·5% pilocarpine to be the same as that of an infusion of 0·01% pilocarpine but to occur 30 min earlier.

The study of the effects of administering pilocarpine to 1 eye showed that there was no detectable effect of that administration on the contralateral untreated eye. It seemed justifiable therefore to investigate different treatments to each of the 2 eyes on 1 occasion in the knowledge that there would be little or no interference between eyes.

We conclude from our results that a continuous infusion of a dilute solution of pilocarpine into the conjunctival sac is as effective in lowering the IOP in glaucoma as a more concentrated solution administered as a drop. The use of dilute solutions of pilocarpine would seem to be likely to reduce the possibility of systemic toxicity. To the advantage of the continuous maintenance by the infusion of an effective concentration in the eye for as long as the infusion is continued may be added the reduction in disturbance of the patient and the reduced nursing time compared with the frequent administration of drops. The principle of continuous infusion is obviously applicable to drugs other than pilocarpine. The use of a small body-borne infusion device allows the patient some degree of mobility during treatment (Bedford et al., 1976).

We thank the patients who co-operated in this investigation and the nursing staff of Nottingham Eye Hospital for their help and forbearance.

References


Intraocular pressure reduction in chronic simple glaucoma by continuous infusion of dilute pilocarpine solution.

A. T. Birmingham, N. R. Galloway and D. A. Walker

*Br J Ophthalmol* 1979 63: 808-812
doi: 10.1136/bjo.63.12.808

Updated information and services can be found at:
http://bjo.bmj.com/content/63/12/808

**These include:**

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/